Traders should monitor the upcoming full financial release and conference call for clarity on gross margins, operating leverage, and whether domestic strength can offset international weakness; sustained Tri-Shield® momentum may support bullish sentiment if profitability improves.
Price Chart
Executive Summary
ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in Tri-Shield® sales. International sales declined 30.2%, and EPS was a loss of $0.31. The company cited ongoing operational challenges from prior backlogs but expressed confidence in its growth strategy.
Key Financial Metrics
Key Facts
- Q1 2026 total sales: $10.4 million, up 28.4% YoY from $8.1 million
- Domestic sales grew 35.7% to $9.7 million
- International sales fell 30.2% to $0.6 million
- Tri-Shield® sales increased 38.5% to $7.9 million
- Dual Force® & Other sales up 4.4% to $2.5 million
- EPS reported as -$0.31, though no consensus estimate was available
- Company hosted a conference call on May 15, 2026, to discuss unaudited results
Financial Impact
Revenue increased by $2.3 million YoY, but international segment declined sharply; net income not disclosed but EPS loss of $0.31 indicates continued unprofitability
Risk Factors
- International sales declined significantly (-30.2%), raising concerns about global demand or distribution
- Ongoing backorder recovery may distort future growth comparisons
- EPS remains negative, indicating continued losses despite revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270500 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $10.79 $10.45 | ▼ −3.15% | ▼ −2.00% | $10.25 (−5.00%) |
May 8, 2026 24w ago | 8-K | $8.45 $9.91 | ▲ +17.28% | ▲ +17.36% | $10.25 (+21.30%) |
Apr 8, 2026 28w ago | 8-K | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.25 (+42.56%) |
Apr 8, 2026 28w ago | Press Release | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.25 (+42.56%) |
Mar 4, 2026 33w ago | 8-K | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.25 (+61.42%) |
Mar 4, 2026 33w ago | Press Release | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.25 (+61.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers